Description
Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.
Product information
CAS Number: 21256-18-8
Molecular Weight: 293.32
Formula: C18H15NO3
Chemical Name: 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
Smiles: OC(=O)CCC1=NC(=C(O1)C1C=CC=CC=1)C1C=CC=CC=1
InChiKey: OFPXSFXSNFPTHF-UHFFFAOYSA-N
InChi: InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : ≥ 100 mg/mL (340.92 mM).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Oxaprozin induces apoptosis in a dose-dependent manner. Oxaprozin increases caspase-3 activity in the activated but not in the resting condition. NF-κB activation is inhibited by 50 μM Oxaprozin. Oxaprozin inhibits activation of the IKK system induced by the reagent IκBα. Oxaprozin dose dependently increase CD40L-treated monocyte apoptosis. 100 μM Oxaprozin induces the strongest proapoptotic effect. 100 μM Oxaprozin significantly increases CD40L-treated monocyte apoptosis. Oxaprozin treatment inhibits CD40L-induced Akt and NF-κB (p65) phosphorylation.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.